Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

被引:3
|
作者
Thomann, Robert [1 ]
Zechmann, Stefan [2 ]
Alexander-David, Nicola
Jornayvaz, Francois R. [3 ]
机构
[1] Burgerspital, Solothurn, Switzerland
[2] Univ Zurich, Inst Primary Care, Zurich, Switzerland
[3] Hop Univ Geneve, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland
关键词
insulin glargine 300 U/mL; type; 2; diabetes; real-world; Switzerland; 100; U/ML; TYPE-2; PEOPLE;
D O I
10.2147/DMSO.S252667
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Insulin glargine 300 U/mL (Gla-300; Toujeo (R)) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100. Patients and Methods: We report the 12 months results of the Swiss cohort of Toujeo-1, a prospective, observational multicenter study exploring the real-world effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on oral therapy and compared these to the overall Toujeo-1 cohort (conducted in Switzerland and Germany). Primary endpoint was the percentage of patients achieving individual HbA1c targets. Secondary endpoints included changes in HbA1c, fasting plasma glucose (FPG), body weight, insulin dose, incidence of hypoglycemia and overall safety. Results: The analysis included 47 patients (14 women) with a mean age of 64.1 years and a diabetes duration of 8.4 years. Swiss physicians determined a higher HbA1c treatment target (7.4 vs. 7.0%) and patients received higher Gla-300 doses at baseline (20.2 vs. 14.7 units/day) and the 12-month follow-up (31.0 vs. 26.2 units/kg) than in the total cohort (n=721). After 12 months, the addition of Gla-300 reduced HbA1c by 1.5% (p<0.0001) to an HbA1c of 7.2%, and FPG by 3.3 mmol/L (p<0.0001) to an FPG of 7.1 mmol/L. At 12 months, 70.2% achieved their individual HbA1c target, more than in the overall Toujeo-1 cohort (49.9%). Body weight remained stable throughout. Only episodes of symptomatic, non-severe hypoglycemic events were documented (2.1%) with similar rates as for the overall Toujeo-1 population. Conclusion: In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.
引用
收藏
页码:2359 / 2365
页数:7
相关论文
共 50 条
  • [21] Empowering Patients During Insulin Initiation: A Real-World Approach
    Barbato, Vincenzo A.
    [J]. JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (07): : 396 - 397
  • [22] Real-world characteristics of patients with type 2 diabetes initiating insulin glargine plus exenatide or insulin glargine plus liraglutide
    Di Genio, A.
    Ling, Z.
    Davis, K. L.
    Meyers, J. L.
    Dalal, M. R.
    [J]. DIABETOLOGIA, 2012, 55 : S328 - S328
  • [23] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naive Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study
    Galstyan, Gagik R.
    Bhansali, Anil
    Vargas-Uricoechea, Hernando
    Tirosh, Amir
    Sun, Guannan
    Naqvi, Mubarak
    Pilorget, Valerie
    Coudert, Mathieu
    Cherkasov, Dmitry
    Khan, Niaz
    [J]. DIABETES, 2020, 69
  • [24] ATOS: REAL-WORLD EFFECTIVENESS AND SAFETY OF INSULIN GLARGINE 300 U/ML IN INSULIN-NAIVE PEOPLE WITH TYPE 2 DIABETES: AD-HOC ANALYSIS OF RUSSIAN POPULATION.
    Galstyan, G.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A98 - A99
  • [25] Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION)
    Al Malki, Faisal
    El Damanhoury, Bandar
    Othman, Abdallah
    Alghamdi, Zain
    AlQahtani, Majed
    Madgy, Amr
    Chouikrat, Zahir
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2869 - 2877
  • [26] Real-world effectiveness
    Schiermeier, Quirin
    [J]. NATURE, 2021, 598 (7882) : 553 - 553
  • [27] Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting
    Boye, Kristina
    Mody, Reema
    Wu, Jianmin
    Lage, Maureen J.
    Botros, Fady T.
    Woodward, Brad
    [J]. DIABETES, 2018, 67
  • [28] Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting
    Boye, Kristina S.
    Mody, Reema
    Wu, Jianmin
    Lage, Maureen J.
    Botros, Fady T.
    Woodward, Brad
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (08) : 1396 - 1407
  • [29] Glargine-300: An updated literature review on randomized controlled trials and real-world studies
    Ghosh, Sujoy
    Ghosh, Romik
    [J]. WORLD JOURNAL OF DIABETES, 2020, 11 (04) : 100 - 114
  • [30] Effectiveness and Safety of the Insulin Degludec U100 vs. Glargine U300 in People with Type 1 diabetes-The IneoxPlus Real-World Study
    De Adana, Maria S. Ruiz, Sr.
    Dominguez-Lopez, Marta E.
    Mora, Maria Del Rosario Vallejo
    Colomo, Natalia
    Linares, Francisca
    Morillas, Virginia
    Herrera, Maria Jose Vallejo
    Gallardo, Silvia Patricia Alonso
    Fuentes, Maria Teresa Padilla
    Vela, Luis I. Navas
    Maldonado-Araque, Cristina
    Olveira, Gabriel
    Martinez, Gemma Rojo
    [J]. DIABETES, 2023, 72